Jade Biosciences (JBIO)

• Market cap: $1.32B
• 1 day: 1.64%
• 5 days: 11.34%
• 1 month: 1.88%
• 3 months: -14.09%
• 6 months: 50.8%
• Year to date: 53.25%
• 1 year: 173.3%
• 5 years: -95.3%
• 10 years: -97.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Employees: 55